Dr. Sujith R. Kalmadi, MD

Dr. Kalmadi practices at Ironwood Cancer & Research Centers in Chandler, Arizona.

Dr. Kalmadi's NPI, 1508973447, was assigned on August 24, 2006. Dr. Kalmadi holds Arizona license 38208.

Dr. Kalmadi's primary practice is Ironwood Cancer & Research Centers, at 695 S Dobson Rd, Chandler, AZ 85224 in Maricopa County. The practice phone is (480) 821-2838.

Dr. Kalmadi's primary practice is Ironwood Cancer & Research Centers in Chandler, Arizona. Dr. Kalmadi is also affiliated with Dignity Health Chandler Regional Medical Center. The medical group on file is Ironwood Cancer & Research Centers. Dmand AI also links Dr. Kalmadi to 4 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kalmadi practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kalmadi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kalmadi is licensed in Arizona.

CMS data shows 185,601 Medicare services from Dr. Kalmadi across 45 procedure codes in 2024, for 833 Medicare patients. Medicare paid $1,594,007 for them.

CMS counts 833 Medicare patients who saw Dr. Kalmadi in 2024. The largest group is 75 to 84, with 357 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.86, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kalmadi's median patient age at 70, with 56% women.

In 2024, Dr. Kalmadi wrote 2,417 Medicare Part D claims for 331 patients. 81% of them were for generic drugs. CMS names the drug for 2,024 of them, across 56 drugs with 11 or more claims each, at $3,345,155 in total drug cost. In 2023, CMS named 2,231 claims across 62 drugs.

Dr. Kalmadi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kalmadi as offering telehealth.

Dmand AI links 5 papers to Dr. Kalmadi, published from 2020 to 2023. 2020 was the busiest year, with 2. Dr. Kalmadi's most frequent co-authors are Ron Bose, MD, William J. Gradishar, MD and Sara A. Hurvitz, MD.

Dmand AI links Dr. Kalmadi to 10 clinical trials, 5 of them phase 3 studies. 3 are still active or recruiting. Conditions studied include Neoplasm Metastasis, Breast Neoplasms and Triple Negative Breast Neoplasms. G1 Therapeutics, Inc. sponsors the most, 2.

CMS Open Payments shows 3,645 general payments to Dr. Kalmadi from 98 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 60% of the total. Janssen Pharmaceuticals, Inc paid the most, $322,061. It also lists 3 research payments totaling $2,210 from 2021 to 2024.